Browse Category

Stock Market News 24 January 2026

Rio Tinto share price ends week higher as broker upgrades sharpen focus on Glencore deadline

Rio Tinto share price ends week higher as broker upgrades sharpen focus on Glencore deadline

Rio Tinto shares closed Friday up 1.39% at £65.76, about 1.5% below their 52-week high. Broker upgrades followed a strong Q4 production update, with copper output boosted by Mongolia’s Oyu Tolgoi. Investors await a Feb. 5 deadline on Glencore talks and annual results on Feb. 19. Trading volume was 1.7 million shares, below the 50-day average.
RELX share price: Kepler’s AI call and buyback update keep the stock in focus ahead of results

RELX share price: Kepler’s AI call and buyback update keep the stock in focus ahead of results

Relx shares closed Friday at 2,921 pence, down 0.14%, marking a fifth straight session of losses. Kepler Cheuvreux maintained a “buy” rating and set a 3,905-pence target, calling AI disruption fears exaggerated and raising its 2026–27 growth outlook. Relx continued its buyback, acquiring 325,221 shares on Jan. 23. Full-year results are due Feb. 12.
Lloyds share price in focus as LLOY heads into results week and BoE rate bets shift

Lloyds share price in focus as LLOY heads into results week and BoE rate bets shift

Lloyds Banking Group shares closed Friday at 101.65 pence, down 0.25%. The bank will report full-year 2025 results on Jan. 29, with investors watching for impacts from shifting UK rate expectations. Lloyds plans to redeem €500 million in floating-rate notes in March 2026. The bank remains under scrutiny after higher provisions linked to the UK motor finance mis-selling scandal.
GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK shares closed down 0.2% at 1,801 pence in London Friday after China approved Trelegy Ellipta for uncontrolled asthma in adults. The expanded label gives GSK access to an estimated 46 million adults with asthma in China. Investors await GSK’s Q4 and full-year results, set for Feb. 4. The FTSE 100 slipped 0.07% on the day.
City Developments stock cools after Thursday pop; S$9.21 close keeps home-price data, Feb results in view

City Developments stock cools after Thursday pop; S$9.21 close keeps home-price data, Feb results in view

City Developments shares fell 0.97% to S$9.21 on Friday, reversing some of Thursday’s gains. Singapore’s private home prices rose 3.3% in 2025, the slowest increase since 2020, according to URA data. CDL begins Newport Residences bookings Jan 31 and will release FY2025 results Feb 27. Construction demand is forecast at S$47-53 billion for 2026.
24 January 2026
Beazley shares rise again as Zurich bid deadline nears — what to watch when London reopens

Beazley shares rise again as Zurich bid deadline nears — what to watch when London reopens

Beazley shares rose 3.2% to £11.52 on Friday but remain below Zurich’s 1,280p takeover offer, which the board rejected as too low. Zurich faces a Feb. 16 deadline to raise its bid or walk away. Beazley’s board cited a previous 1,315p approach and set March 4 for full-year results. Investors are watching for any revised offer or new bidders.
Genting Singapore stock price holds at S$0.73 — what could move SGX:G13 next week

Genting Singapore stock price holds at S$0.73 — what could move SGX:G13 next week

Genting Singapore closed flat at S$0.730 on Friday, with 33.6 million shares traded as the Straits Times Index hit a record high. The stock moved between S$0.725 and S$0.735 during the session. The company will report full-year results on Feb. 24 after market close. Resorts World Sentosa’s casino licence was renewed for two years amid concerns over tourism figures.

Stock Market Today

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
New York, Feb 7, 2026, 11:29 ET — Market closed. AbbVie shares closed up 2% on Friday at $223.43, extending a second straight session of gains as U.S. stocks rallied. The stock is still roughly 9% below its 52-week high, and trading volume ran a bit under its recent average. (MarketWatch) The bounce comes as investors work through AbbVie’s post-earnings reset and what it means for 2026. The drugmaker said fourth-quarter net revenues rose 10% to $16.618 billion and adjusted profit per share—excluding certain items—was $2.71; it forecast 2026 adjusted earnings of $14.37 to $14.57 a share. Chief Executive Robert
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

7 February 2026
Bank of America shares rose 2.89% Friday to $56.53, tracking a rally in U.S. financial stocks as the Dow closed above 50,000. The bank will redeem its Series DD preferred stock and related depositary shares on March 10 at $1,000 per share. CEO Brian Moynihan donated 100,000 shares on Feb. 4, a regulatory filing showed. Key U.S. jobs and inflation data are due next week after delays.
Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

7 February 2026
Oracle shares jumped 4.65% to $142.82 Friday, ending an eight-day slide but remaining down 22% since Jan. 27. The company has set up a $20 billion at-the-market stock program and completed a $25 billion senior notes sale to fund cloud expansion. Oracle’s liabilities stood at $174.5 billion as of Nov. 30, 2025, before the new financing. Investors remain focused on dilution risks and the pace of capacity growth.
Go toTop